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Ethnographic  relevance:  Clinical  trials  investigating  Chinese  herbal  medicine  (CHM)  have  been  frequently
criticised  for  their  lack  of  scientiﬁc  rigour.  As part  of  the  GP-TCM  project  a team  of experienced  clini-
cal  researchers  and  CHM  practitioners  have  developed  clinical  trial guidelines  for  CHM  that  combine  an
appreciation  for  traditional  methods  of  practice  with  detailed  and  practical  advice  on  research  method-
ology.
Materials  and  methods:  This  paper  presents  an  executive  summary  of  this  work.  It introduces  the  practice
of CHM  and  the  key  considerations  that need  to  be  addressed  whilst  researching  this  traditional  medical
system.raditional Chinese medicine
ystems biology and omics
uality traditional medicines
Results:  These  guidelines  emphasise  the  importance  of  identifying  best  practice,  and  then  developing  and
applying  appropriate  and  rigorous  research  methodologies  to investigate  CHM  as  a  whole  system.
Conclusions:  It  is  hoped  that  this  will encourage  a thoughtful  and  meticulous  process  of investigation  that
will clarify  the contribution  that CHM can  make  to  our  future  healthcare.  Innovative  new  approaches  are
considered  including  the  application  of  the  new  “omic”  technologies  and  systems  biology  as  a  way  of
enhancing  our  understanding  of  traditional  practice. Background
Our primary aim in developing these guidelines was to improve
nd develop randomised controlled trial (RCT) methodologies to
nvestigate the clinical practice of Chinese herbal medicine (CHM).
he quality of clinical research in this area has been perceived as a
ajor issue for many years by researchers, clinicians and regulator
uthorities’ internationally. The GP-TCM consortium (GP-TCM) has
rovided the ideal environment to develop this process initially for
he European Union. The guidelines were developed by a team of
xperienced researchers from the EU and China as part of the GP-
CM project over a period from October 2010 to July 2011 and are
vailable via the GP-TCM website (GP-TCM). Particular attention
as been paid to address the dilemma of maintaining the integrity
f the practice of Chinese medicine (CM) and the complex, whole
ystems nature of CHM interventions, whilst subjecting CHM to
obust research methodologies to investigate its safety and effec-
iveness. Various stages in the research process are described and
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discussed and practical information on the design and implementa-
tion of a protocol is provided. Finally the new “omic” technologies
are introduced as a means of employing the latest approaches in
systems biology to model and deepen our understanding of the
therapeutic pathways that may  be involved in CHM.
This is intended as a practical document that can be used freely
by CHM researchers from the initial stages of conception, through
trial design and development, to the ﬁnal process of reporting
results. It is a consensus document that will inevitably evolve over
time and through debate, evidence, and will be useful to national
and international drug regulatory authorities.
2. Special considerations for CHM research
CHM is one component of CM that incorporates other treat-
ment modalities such as acupuncture, moxibustion, tuina and qi
gong (Maciocia, 1989). It has its own  distinctive understanding
of the causation and pathological process of disease, systematic
Open access under CC BY-NC-ND license.methods of diagnosing and categorising illness, and a sophisticated
approach to treatment of disease and health maintenance. CHM
has a recorded history of over 2000 years (Unschuld, 1998). Dur-
ing its long history it has developed into many diverse forms of
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p
t
o
t
f
i
c
t
d
a
t
r
t
d
p
i
a
o
a
s
f
C
o
p
t
e
3
1
Table 1
Matching a research question with an appropriate methodology.
Research question Methodology
What is the efﬁcacy of CHM for a
speciﬁc disease or condition?
Placebo-controlled, double-blind,
randomised clinical trial
What is the effectiveness of CHM
in real world practice?
Pragmatic randomised trial
Are  there side effects from CHM? Observational study-longitudinal
survey
Case controlled study
What is the patient’s experience of
taking CHM?
Qualitative research
Which conditions seem to respond
well to CHM?
Patient registries
Observational study
Cross sectional survey of
practitioners
What are the active ingredients of
a particular herb?
Laboratory experimentationA. Flower et al. / Journal of Ethn
ractice that are now common in East Asian countries, and appear
o be making an increasing impact on healthcare systems through-
ut the world (Scheid, 2002). This has perhaps been accelerated by
he development and marketing of effective pharmaceutical agents
rom herbs such as Artemisinin from Artemisiae annuae L. Despite
ts diversity and the depth of pharmacological evidence for the spe-
iﬁc efﬁcacy of herbs we believe there are several key components
hat unite the practice of CHM and that need to be considered when
eveloping a CHM research programme.
Best practice of CHM is usually considered to involve providing
n individualised treatment that may  change over time in response
o the health status of the recipient. Until recently the commonest
oute to deliver CHM was via water based herbal soups or decoc-
ions (Bensky and Gamble, 1986). Since the 1960s new methods of
elivering CHM have emerged including the use of concentrated
owders, extracts, and injections. These guidelines discuss the var-
ous merits and shortcomings of the available delivery options,
nd propose a staged investigation of CHM, from traditional meth-
ds of practice to the more standardised, processed, and reﬁned
pproaches that suit a modern pharmacological investigation. This
hould create an appropriate and scientiﬁcally rigorous pathway
or the development of an effective, licensed, and widely available
HM products. We  have chosen this strategic route in recognition
f the knowledge embedded within CM over centuries of clinical
ractice but are by no means wedded to the belief that long term
raditional use of a speciﬁc herb or herbal mixture can be taken as
vidence of effectiveness or safety.
. Key recommendations
. Research ideas should emerge from positive experience in
clinical practice and address current “effectiveness gaps” in con-
ventional medicine, where treatment is either ineffective or
associated with unacceptable adverse effects (Shan and Chi Ho,
2011). The design of the research should be tailored to provide
the kind of information required by the main research stakehold-
ers which is likely to include pragmatic and cost effectiveness
studies.
It is essential that the research methodology that is selected
is appropriate to answer the speciﬁc research question (see
Table 1). These guidelines discuss how, for example, to inves-
tigate the speciﬁc efﬁcacy of CHM, in the context of rigorously
designed double blinded, explanatory trials, with a relatively
homogenous population using a single intervention versus a
control intervention. However, if we are considering the inves-
tigation of the ‘real world’ effectiveness of CHM, then pragmatic
Fig. 1. The relationship between the research question What is the economic cost of CHM
for treating a disease?
Health economic evaluation
trials with a heterogeneous population receiving more naturalis-
tic treatment (that may  include modalities such as acupuncture
or tuina) should be used (see Fig. 1). Different research methods
including N-of-1 trials, cross over studies, and factorial designs
are introduced in the guidelines to encourage ﬂexibility and
sophistication in trial design. An N-of-1 trial may  involve an indi-
vidual being randomly assigned to Treatment A for a period of
time before being switching to either an active or a placebo Treat-
ment B, is a more controlled version of the case study that has
informed CHM practice for hundreds of years.
The guidelines also discuss the value of qualitative research as
a means of providing a deeper, more patient centred account of
receiving CHM treatment. These approaches can be incorporated
into quantitative mixed method designs to explore the complex
nature of CHM intervention (see Table 3).
2. The development of a CHM research project should follow the
UK Medical Research Council (MRC) guidelines for investigat-
ing a complex intervention (Craig et al., 2008). These guidelines
describe mutually informing phases of research, rather than
a simple linear progression. They recommend paying careful
attention to model validity/best practice in the initial Develop-
mental phases of research. These are then tested and reﬁned
in a Feasibility stage, before a more rigorous assessment in an
Evaluation phase that will use models involving adequately pow-
ered and properly managed randomised clinical trials. Finally an
Implementation phase assesses the ‘real world’ and long-term
and the corresponding study design (Witt, 2009).
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Table 2
Pattern diagnosis and treatment in traditional Chinese medicine.
Symptoms and signs Pattern differentiation Treatment principles Guiding formula “Xiao Yao San” Individualised formula
Poor appetite
Bloating
Loose stools
Pale tongue
Spleen Qi deﬁciency Invigorate the spleen Chai Hu
Bai Shao
Dang Gui
Bai Zhu
Fu Ling
Bo He
Sheng Jiang
Gan Cao
Chai Hu
Bai Shao
Dang Gui
Gou Qi Zi
Bai Zhu
Fu Ling
Chen Pi
Yu Jin
Ju Hua
Sheng Jiang
Dizziness
Blurred vision
Fatigue
Pale tongue
Thready pulse
Blood deﬁciency Nourish blood
Premenstrual tension Liver Qi stagnation Harmonise the liver
3
4
T
QTemporal headaches
Wiry pulse
contribution that CHM makes to health care, and identiﬁes areas
for future research. During these research phases it will be neces-
sary to adopt different research methods to address the different
research questions being addressed (see Table 1).
Deﬁning best practice is a complex process that includes the
CHM notions of causation, patho-physiology, and disease treat-
ment. We  consider it is essential that CHM is investigated using
a pragmatic and experiential based approach to create the best
possible intervention, based on the information available, for the
proposed study and study participants. An example of how var-
ious symptoms are grouped into patterns or syndromes, which
then inform a choice of classical herbal formula that may  then
be individualised for a particular patient is given in Table 2. This
approach is apparent in a recently published CHM paper describ-
ing a two-stage trial protocol. In the initial open phase a CM
syndrome pattern that appears more responsive to a particular
CHM intervention is identiﬁed. This is then followed by a sec-
ond phase, double-blinded RCT, which only enrols participants
presenting with this syndrome (Zhang et al., 2011).
. We  may  eventually have a much greater understanding of the
science involved which should then allow us to move away from
this experiential approach but until we do so, it is essential that
we recognise, evaluate, and work with this accumulated clini-
cal experience. Deﬁning best practice should involve reﬂective
practice, a literature review (to include available research, con-
temporary text books and, where possible, classical CHM texts),
and some form of peer review that provides a professional con-
sensus to support the CHM treatment used within any clinical
trial.
. In the design of treatment protocols using CHM herbal treatment
may  be:
• Individualised:  where each participant is given an individu-
alised prescription that may  change over time. This is generally
considered as the optimum way to deliver safe and effective
CHM in most parts of the world.
• Semi-standardised: using CHM patterns or syndromes of dis-
ease to inform treatment or inclusion into a clinical trial to
provide broadly targeted treatment.
• Standardised: this involves a single remedy being used for
all participants in a trial. It has the advantage of making the
able 3
ualitative research questions in CHM.
Research question Methods of dat
What is the patient’s and CHM practitioners’ experience,
knowledge, attitudes and barriers of taking CHM? (Xu et al.,
2006)
Interviews; foc
What  is involved within the whole consultation between CHM
practitioners and patients? And how does it happen? (Yu
et  al., 2010)
participant obs
non-participan
(Yu and Liu, 20Gan Cao
ﬁndings of the trial more generaliseable but it does not con-
form to the generally held notions of best CHM practice.
We  recommend that research progresses through these stages.
Whilst it may  not be practical to run an individualised trial, it is
relatively straightforward to conduct clinical audits on individu-
alised cases. These can then be used to help deﬁne best practice
and may  lead to the identiﬁcation of 2 or 3 commonly occurring
key syndromes and a narrow range of herbs that could be used
in a semi-standardised research design. A generic treatment can
also be developed to include beneﬁts for the range of identiﬁed
syndromes if appropriate.
5. Methods of CHM administration:
The delivery of CHM usually involves herbal formulae that may
range in the number of ingredients from a single herb to complex
formulae of over 20 ingredients. Typically though a CHM formula
includes between 8 and 15 herbs that are divided into those with
the primary therapeutic action (the ‘Emperor’ herbs); those that
support this action and address other co-existing patterns (the
‘Minister’ herbs); those that reinforce the primary therapeutic
agents and act to reduce adverse events (the ‘Assistant’ herbs);
and ﬁnally the ‘Envoy’ herbs that focus the formula on a partic-
ular part or system of the body. There are several methods that
can be used to administer CHM. Traditional use generally favours
protracted boiling of the herbs to make decoctions, although
alcoholic extracts and herbal pills are also commonly mentioned
in the classical records. In recent years concentrated powdered
extracts have become an increasingly common method of dis-
pensing CHM. The use of these powders is potentially a great
boom for producers, regulators and patients from the perspec-
tive of manufacture, quality control, reproducibility of product,
patient adherence to the recommended treatment and subse-
quent marketing.
Best practice in China has been considered to involve the use
of herbal decoctions (Bensky and Gamble, 1986) in order to pre-
serve the range of the traditional synergies that may underpin
the therapeutic effects of CHM. Taiwan and other Asian coun-
tries (Japan and Korea) are now increasingly using concentrated
herbal powders as the basis for their prescriptions. Whilst this
allows the production of a convenient, quality assured prod-
uct there is some chromatographic evidence to suggest that
a collecting Methods of data analysing
us group Framework analysis; thematic analysis;
grounded theory (Green and Thorogood, 2004)
ervation;
t observation; interview
08)
Conversation analysis; thematic analysis (Liu,
2009)
ophar
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the manufacturing process for concentrated powders leads to
a reduction in known active compounds (Chen et al., 2009; Ma
et al., 2006). However, a recent systematic review reported in
the current issue of this journal, provides very preliminary evi-
dence that calls the clinical implications of this assumption into
question (ref) and suggests that concentrated powders may  be
as clinically effective as herbal decoctions. At present there is
no deﬁnitive answer to this question. For the purposes of these
guidelines the recommendations are:
• to include herbal decoctions at some stage of the CHM research
process. This may  be as part of a clinical audit, prospective
observational study, or case series but it has been shown that
rigorous double-blinded RCTs are possible with individualised
CHM decoctions (Flower et al., 2011; Lechner et al., 2011);
• if it is not possible, for ﬁnancial or pragmatic reasons, to use
decoctions in a trial setting, then we recommend using concen-
trated powders derived from herbal decoctions, rather than
simply aggregating the individual herbal powders. We  con-
sider that this will incorporate the traditional compositions of
ingredients (formed during the preparation of the decoctions)
that are probably important to the effectiveness and safety of
CHM;
• if this is not possible, and only aggregated individual herb pow-
ders should be used, then this should be clearly recorded in the
report of the trial methodology.
. Blinding and randomisation
Although there are more than 17,000 RCTs currently published
within the Chinese database (Tang et al., 1999; Wang et al., 2007),
it has been estimated that less than 5% of these conform to
internationally acceptable research standards (Wu  et al., 2008)
with respect to blinding and randomisation. The main causes
for this are misconceptions about the meaning of these terms
and the practical requirements for adequate blinding and ran-
domisation. These guidelines, which will be available to Chinese
researchers, describe several methods of randomisation that are
appropriate to a variety of different clinical and research con-
texts and discuss issues relating to the importance of blinding in
CHM clinical trials. It is hoped that they will lead to an increase
in the standard and rigour of Chinese and European clinical trials
that will prevent wasteful research and facilitate a more rigorous
investigation of CHM.
. Conducting a clinical trial:
The guidelines introduce the key components required to
conduct a clinical trial. These include the complex ethical
and legal considerations in the EU and in China that need
to be taken into account before a trial can commence, such
as the importance of a clear and consensus based study
protocol, registering a trial on an international database, gain-
ing ethical approval for the trial protocol, and using herbal
products that meet the required standards for Good Man-
ufacturing and Good Agricultural practice (GMP and GAP).
Information is provided on how to access the various govern-
ment agencies responsible for regulating these aspects of clinical
trials.
There are also detailed sections in the guidelines on how
to develop a trial protocol, discussion of the kinds of out-
comes measures that should be used (including areas such as
health economic analysis that are routinely neglected in CHM
trials), the importance of long term follow up to detect sus-
tained improvements in health and changes in rates of disease
reoccurrence, and recommendations on how results should be
reported, disseminated and implemented in accordance with
the latest herbal CONSORT requirements. Particular emphasis is
made to using accurate botanical nomenclature, and providing
detailed accounts of how herbs are prepared and administered.
The guidelines also propose the biochemical proﬁling of herbalmacology 140 (2012) 550– 554 553
medicines used in a trial to safeguard the comparability of
different studies, and to enable research that may  be controver-
sial to be reproduced.
8. The role of “omic” technologies and systems biology approaches
in CHM research:
The development and application of the “omic” technologies
is in the process of signiﬁcantly changing research perspectives
towards traditional medicines including CHM (Ulrich-Merzenich
et al., 2007). With the “omic”-technologies, a multitude of
molecules on the genetic level (genomics, transcriptomics),
the protein level (proteomics), or at the level of metabolites
(metabolomics), can be estimated simultaneously, providing an
innovative technological platform for an analysis of the com-
position of complex mixtures and their multi-targeted mode of
actions. At the same time system biology approaches aimed at
obtaining, integrating and analysing complex data sets from dif-
ferent sources using interdisciplinary tools will provide a better
understanding of causes and effects in biological networks (Van
Wietmarschen et al., 2009).
These developments mean that the search for single “active
principles” in plants, based on the assumption that a plant has
one or a few ingredients that determine its therapeutic effects,
can now evolve into an approach that is more appropriate to tra-
ditional systems of medicine like CHM and conceptually link the
approaches used in TCM with systems biology and the emerg-
ing technology of individualising medicines in accordance with
a person’s biological variability. In these systems it is generally
assumed that overadditive or synergistic effects of all ingredients
of the plant(s) will bring about the maximum therapeutic efﬁ-
cacy. The “omic”-technologies provide a promising tool to cope
with the analytic challenges arising from this approach and the
guidelines discuss their potential contribution in several differ-
ent domains:
• authenticity and quality of plant material;
• analysis of the mode of action of single plants and multi-
component mixtures;
• assessment of the toxicity of CHM;
• drug metabolisation (individual drug responses);
• integration of Chinese medicine patterns into Western diag-
nostics.
4. Conclusion
These guidelines introduce the practice of CHM and describe
key considerations that need to be addressed in the development of
rigorous research methods for this traditional medical system. They
emphasise the importance of identifying best practice, and then
developing appropriate research methodologies to subject CHM to
scientiﬁc scrutiny. It is hoped that these guidelines encourage a
thoughtful and systematic process of investigation that will clarify
the contribution that CHM can make to our future healthcare.
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